Subtopic Deep Dive
CRISPR Delivery Systems
Research Guide
What is CRISPR Delivery Systems?
CRISPR Delivery Systems encompass methods including viral vectors, nanoparticles, and electroporation to transport CRISPR components into cells for efficient in vivo genome editing.
Researchers evaluate AAV, lentiviral vectors, lipid nanoparticles, and physical methods like electroporation for CRISPR delivery, focusing on tissue specificity, immune responses, and editing efficiency. Over 20 papers from 2013-2020 address these platforms, with foundational work on AAV-CRISPR systems (Senís et al., 2014; 259 citations). Recent reviews highlight clinical translation challenges (Lino et al., 2018; 1140 citations).
Why It Matters
CRISPR delivery systems enable in vivo therapies for genetic diseases by overcoming barriers like immunogenicity and off-target effects, as shown in AAV-CRISPR for muscle editing (Chew et al., 2016; 616 citations). Lentiviral vectors support stable integration in hematopoietic cells for cancer modeling (Platt et al., 2014; 1977 citations; Milone and O’Doherty, 2018; 828 citations). Nanoparticles improve RNA delivery for transient editing, advancing clinical trials (Kaczmarek et al., 2017; 620 citations). These platforms bridge preclinical models to human applications, with Lino et al. (2018) detailing translation hurdles.
Key Research Challenges
Immunogenicity of Viral Vectors
AAV and lentiviral vectors trigger immune responses that limit repeat dosing and efficacy in vivo (Chew et al., 2016). Pre-existing antibodies reduce transduction in humans (Milone and O’Doherty, 2018). Engineering low-immunogenic capsids remains critical (Senís et al., 2014).
Tissue-Specific Targeting
Delivery platforms exhibit variable tropism, hindering editing in non-liver tissues like brain or muscle (Platt et al., 2014). Nanoparticles offer customization but face stability issues (Kaczmarek et al., 2017). Optimizing serotypes for specific organs is ongoing (Kim et al., 2017).
Cargo Size Limitations
Large CRISPR-Cas9 components exceed AAV packaging capacity, requiring split systems or smaller orthologues (Kim et al., 2017; 722 citations). This reduces editing efficiency in multiplex applications (Zetsche et al., 2016). Balancing payload and delivery vehicle remains key (Lino et al., 2018).
Essential Papers
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Randall J. Platt, Sidi Chen, Yang Zhou et al. · 2014 · Cell · 2.0K citations
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
Hongyi Li, Yang Yang, Weiqi Hong et al. · 2020 · Signal Transduction and Targeted Therapy · 1.6K citations
Abstract Based on engineered or bacterial nucleases, the development of genome editing technologies has opened up the possibility of directly targeting and modifying genomic sequences in almost all...
The CRISPR tool kit for genome editing and beyond
Mazhar Adli · 2018 · Nature Communications · 1.6K citations
Abstract CRISPR is becoming an indispensable tool in biological research. Once known as the bacterial immune system against invading viruses, the programmable capacity of the Cas9 enzyme is now rev...
CRISPR/Cas9 in Genome Editing and Beyond
Haifeng Wang, Marie La Russa, Lei S. Qi · 2016 · Annual Review of Biochemistry · 1.2K citations
The Cas9 protein (CRISPR-associated protein 9), derived from type II CRISPR (clustered regularly interspaced short palindromic repeats) bacterial immune systems, is emerging as a powerful tool for ...
Delivering CRISPR: a review of the challenges and approaches
Christopher A. Lino, Jason C. Harper, James P. Carney et al. · 2018 · Drug Delivery · 1.1K citations
Gene therapy has long held promise to correct a variety of human diseases and defects. Discovery of the Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR), the mechanism of the CRIS...
Multiplex gene editing by CRISPR–Cpf1 using a single crRNA array
Bernd Zetsche, Matthias Heidenreich, Prarthana Mohanraju et al. · 2016 · Nature Biotechnology · 947 citations
Clinical use of lentiviral vectors
Michael C. Milone, Una O’Doherty · 2018 · Leukemia · 828 citations
Reading Guide
Foundational Papers
Start with Platt et al. (2014; 1977 citations) for knockin mouse delivery via CRISPR and Senís et al. (2014; 259 citations) for AAV toolbox, as they establish viral vector benchmarks. Kaufmann et al. (2013; 270 citations) contextualizes gene therapy vectors.
Recent Advances
Study Lino et al. (2018; 1140 citations) for comprehensive challenges review and Kaczmarek et al. (2017; 620 citations) for RNA nanoparticle advances. Kim et al. (2017; 722 citations) highlights small Cas9 orthologues for better packaging.
Core Methods
Core techniques: AAV serotype engineering (Senís et al., 2014), lentiviral integration (Milone and O’Doherty, 2018), lipid nanoparticles for RNP delivery (Kaczmarek et al., 2017), and electroporation for ex vivo editing (Platt et al., 2014).
How PapersFlow Helps You Research CRISPR Delivery Systems
Discover & Search
Research Agent uses searchPapers and citationGraph to map delivery vectors from seed paper 'Delivering CRISPR: a review of the challenges and approaches' (Lino et al., 2018; 1140 citations), revealing clusters around AAV (Senís et al., 2014) and nanoparticles (Kaczmarek et al., 2017). exaSearch uncovers unpublished preprints on electroporation, while findSimilarPapers expands to lentiviral works (Milone and O’Doherty, 2018).
Analyze & Verify
Analysis Agent employs readPaperContent on Chew et al. (2016) to extract host response data, then verifyResponse with CoVe cross-checks immunogenicity claims against Platt et al. (2014). runPythonAnalysis processes editing efficiency stats from multiple papers using pandas for meta-analysis and GRADE grading for evidence strength on AAV tropism. Statistical verification confirms immune evasion trends.
Synthesize & Write
Synthesis Agent detects gaps in nanoparticle immunogenicity via contradiction flagging across Lino et al. (2018) and Kaczmarek et al. (2017), generating exportMermaid diagrams of delivery comparisons. Writing Agent uses latexEditText and latexSyncCitations to draft therapy protocols citing 10+ papers, with latexCompile producing camera-ready reviews and gap hypotheses for clinical translation.
Use Cases
"Compare editing efficiency of AAV vs nanoparticles for liver CRISPR in mouse models"
Research Agent → searchPapers + citationGraph → Analysis Agent → runPythonAnalysis (pandas meta-analysis of efficiencies from Chew et al. 2016 and Kaczmarek et al. 2017) → bar chart output with GRADE scores.
"Write a review section on lentiviral CRISPR delivery immunogenicity"
Research Agent → findSimilarPapers (Milone and O’Doherty 2018) → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations + latexCompile → LaTeX section with figures.
"Find code for simulating AAV tropism in CRISPR delivery"
Research Agent → paperExtractUrls (from Senís et al. 2014) → Code Discovery → paperFindGithubRepo → githubRepoInspect → Python sandbox verification of tropism models.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ delivery papers, chaining searchPapers → citationGraph → DeepScan for 7-step verification on immunogenicity data from Chew et al. (2016). Theorizer generates hypotheses on hybrid AAV-nanoparticle systems by synthesizing gaps in Lino et al. (2018) and Kim et al. (2017). DeepScan applies CoVe checkpoints to validate tropism claims across foundational works.
Frequently Asked Questions
What defines CRISPR Delivery Systems?
CRISPR Delivery Systems are methods like viral vectors (AAV, lentivirus), nanoparticles, and electroporation to introduce Cas9 and guide RNA into target cells (Lino et al., 2018).
What are common delivery methods?
Viral methods include AAV (Senís et al., 2014; Chew et al., 2016) and lentivirus (Milone and O’Doherty, 2018); non-viral include nanoparticles (Kaczmarek et al., 2017) and cell-penetrating peptides (Liu et al., 2014).
What are key papers on CRISPR delivery?
Lino et al. (2018; 1140 citations) reviews challenges; Chew et al. (2016; 616 citations) details AAV-CRISPR responses; Senís et al. (2014; 259 citations) provides AAV toolbox.
What are open problems in CRISPR delivery?
Challenges include reducing immunogenicity (Chew et al., 2016), expanding tissue tropism beyond liver (Kim et al., 2017), and overcoming cargo size limits for full Cas9 (Zetsche et al., 2016).
Research CRISPR and Genetic Engineering with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching CRISPR Delivery Systems with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the CRISPR and Genetic Engineering Research Guide